Jeffrey W Tyner

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Activating alleles of JAK3 in acute megakaryoblastic leukemia
    Denise K Walters
    Howard Hughes Medical Institute, Portland, Oregon 97239, USA
    Cancer Cell 10:65-75. 2006
  2. pmc High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
    Marc M Loriaux
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Blood 111:4788-96. 2008
  3. pmc Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia
    Vincent T Bicocca
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Cell 22:656-67. 2012
  4. pmc MET receptor sequence variants R970C and T992I lack transforming capacity
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Res 70:6233-7. 2010
  5. pmc PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma
    M Imran Aslam
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239
    Proc Natl Acad Sci U S A 111:6383-8. 2014
  6. pmc The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
    Christopher A Eide
    Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA
    Cancer Res 71:3189-95. 2011
  7. pmc RNAi screen for rapid therapeutic target identification in leukemia patients
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Proc Natl Acad Sci U S A 106:8695-700. 2009
  8. pmc CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
    Jeffrey W Tyner
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 115:5232-40. 2010
  9. pmc SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
    Thomas O'Hare
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Proc Natl Acad Sci U S A 105:5507-12. 2008
  10. pmc Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
    Monika A Davare
    Knight Cancer Institute, Howard Hughes Medical Institute, and Departments of Biochemistry and Molecular Biology and Cell and Developmental Biology, Oregon Health and Sciences University, Portland, OR 97239
    Proc Natl Acad Sci U S A 110:19519-24. 2013

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Activating alleles of JAK3 in acute megakaryoblastic leukemia
    Denise K Walters
    Howard Hughes Medical Institute, Portland, Oregon 97239, USA
    Cancer Cell 10:65-75. 2006
    ..These findings illustrate the biological importance of gain-of-function JAK3 mutations in leukemogenesis and demonstrate the utility of proteomic approaches to identifying clinically relevant mutations...
  2. pmc High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
    Marc M Loriaux
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Blood 111:4788-96. 2008
    ....
  3. pmc Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia
    Vincent T Bicocca
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Cell 22:656-67. 2012
    ..Consequently, ROR1 silencing accentuates dasatinib killing of t(1;19) ALL cells...
  4. pmc MET receptor sequence variants R970C and T992I lack transforming capacity
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Res 70:6233-7. 2010
    ....
  5. pmc PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma
    M Imran Aslam
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239
    Proc Natl Acad Sci U S A 111:6383-8. 2014
    ....
  6. pmc The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
    Christopher A Eide
    Oregon Health and Science University, Knight Cancer Institute, Portland, OR, USA
    Cancer Res 71:3189-95. 2011
    ..Taken together, these findings support continued evaluation of DCC-2036 as an important new agent for treatment-refractory CML...
  7. pmc RNAi screen for rapid therapeutic target identification in leukemia patients
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Proc Natl Acad Sci U S A 106:8695-700. 2009
    ..Combination of this technique with whole-genome sequencing will represent an ideal tool for oncogenic target identification such that specific therapies can be matched with individual patients...
  8. pmc CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
    Jeffrey W Tyner
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 115:5232-40. 2010
    ....
  9. pmc SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
    Thomas O'Hare
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Proc Natl Acad Sci U S A 105:5507-12. 2008
    ..These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia...
  10. pmc Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
    Monika A Davare
    Knight Cancer Institute, Howard Hughes Medical Institute, and Departments of Biochemistry and Molecular Biology and Cell and Developmental Biology, Oregon Health and Sciences University, Portland, OR 97239
    Proc Natl Acad Sci U S A 110:19519-24. 2013
    ..Taken together, our data strongly suggest that foretinib is a highly effective ROS1 inhibitor, and further clinical investigation to evaluate its potential therapeutic benefit for patients with ROS1-driven malignancies is warranted. ..
  11. pmc An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma
    Jinu Abraham
    Pediatric Cancer Biology Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Biochem Biophys Res Commun 426:363-8. 2012
    ..These results suggest that an adaptive Src-Pdgfra-Raf-Mapk axis is relevant to PDGFRA inhibition in rhabdomyosarcoma...
  12. pmc In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
    Jason M Glover
    Division of Pediatric Hematology and Oncology, Department of Pediatrics, Knight Cancer Institute, Doernbecher s Childrens Hospital, Oregon Health and Science University, Portland, Oregon, USA
    Pediatr Blood Cancer 59:576-9. 2012
    ..Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL...
  13. pmc RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, USA
    Blood 111:2238-45. 2008
    ..This technique, with additional development, might eventually offer the potential to match specific therapies with individual patients based on a functional assay...
  14. pmc High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
    Jeffrey W Tyner
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Blood 113:1749-55. 2009
    ....
  15. pmc Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
    Jeffrey W Tyner
    Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97239, USA
    Cancer Res 73:285-96. 2013
    ..Taken together, our results suggested that drug target scores derived from a comprehensive kinase inhibitor panel could predict pathway dependence in cancer cells while simultaneously identifying potential therapeutic options...
  16. pmc The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
    Stephen E Spurgeon
    Knight Cancer Institute, Oregon Health and Science University, 3181 Sam Jackson Park Road, Portland, OR 97239, USA
    J Pharmacol Exp Ther 344:378-87. 2013
    ..Our findings support the ongoing development of P505-15 as a therapeutic agent for B-cell malignancies. A dose finding study in healthy volunteers has been completed...
  17. pmc The PI3K/Akt1 pathway enhances steady-state levels of FANCL
    Kim Hien T Dao
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Mol Biol Cell 24:2582-92. 2013
    ....
  18. pmc HitWalker: variant prioritization for personalized functional cancer genomics
    Daniel Bottomly
    Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Bioinformatics 29:509-10. 2013
    ..Availability and implementation: The program, documentation and example data are available as an R package from www.biodevlab.org/HitWalker.html...
  19. pmc AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    Thomas O'Hare
    Division of Hematology and Medical Oncology, Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Cancer Cell 16:401-12. 2009
    ..Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML...
  20. pmc Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies
    Kim Hien T Dao
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland 97239, Oregon, USA
    Clin Cancer Res 19:1309-11. 2013
    ..Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies...
  21. pmc Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML
    Julia E Maxson
    Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    N Engl J Med 368:1781-90. 2013
    ....
  22. pmc Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma
    M Imran Aslam
    Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, MC L321, Portland, OR 97239
    Mol Cancer Res 11:1303-13. 2013
    ..Implications: RTK expression status and subcellular localization dynamics are important considerations for personalized medicine...
  23. doi request reprint A case study of personalized therapy for osteosarcoma
    Lara E Davis
    Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health and Sciences University, Portland, Oregon 80523 1620, USA
    Pediatr Blood Cancer 60:1313-9. 2013
    ..Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma...
  24. pmc p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes
    Praveen Anur
    Oregon Health and Science University, Portland, OR, USA
    Blood 119:1992-2002. 2012
    ....
  25. pmc A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma
    Molly F Kulesz-Martin
    Knight Cancer Institute and Department of Dermatology, Oregon Health and Science University, Portland, OR, USA and ryanc ohsu edu
    Cancer Biol Ther 14:95-9. 2013
    ..Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC...